RAO Davao City

United States Military Retiree Activities Office Davao City, Philippines


Posted by Service Officer on July 31st, 2008

This year, according to the American Cancer Society, an estimated 186,000 men in the U.S. will be diagnosed with prostate cancer, and about 28,000 will die from the disease. According to phase-I clinical results published in the Journal of Clinical Oncology on 22 JUL, a new drug, abiraterone, dramatically shrunk the size of tumors and offered lasting benefits for prostate patients, compared with existing treatments. Researchers found that this experimental drug showed significant benefits for men who had exhausted all other treatments. Though it is in early development, many cancer doctors are optimistic about abiraterone. Cougar Biotechnology Inc., who sponsored the trial, says the drug could be approved for sale in the U.S. as early as 2011, if all goes well. Initial findings suggest more patients with advanced prostate cancer respond to abiraterone than other drugs in development. There is also evidence the tumors shrink more on this drug and that benefits last longer, in some cases, a year and a half. Prostate cancers are fueled by testosterone. This drug lowers the levels of testosterone below what can be achieved with other drugs. The next step is a much larger, international clinical trial, which is currently enrolling patients. The goal is to determine whether the many benefits of this drug translate into prolonged survival for patients, the way it has for current trial users. [Source: ABC Medical News John McKenzie article 23 Jul 08 ++]

Leave a Reply

You must be logged in to post a comment.